Genentech, AC Immune in $421M Alzheimer's Deal
By Cormac Sheridan
Tuesday, June 19, 2012
Genentech, a member of the Roche Group, exhibited its evident enthusiasm for AC Immune SA's pipeline of antibodies in development for Alzheimer's disease, by in-licensing the company's preclinical tau-targeting program in a deal potentially worth upward of CHF400 million (US$421 million) in up-front plus research, development and sales-associated milestone payments.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.